<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">34731254</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>24</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cellular and molecular life sciences : CMLS</Title><ISOAbbreviation>Cell Mol Life Sci</ISOAbbreviation></Journal><ArticleTitle>Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants.</ArticleTitle><Pagination><MedlinePgn>7967-7989</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-021-04008-0</ELocationID><Abstract><AbstractText>Since the emergence of the first case of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), the viral genome has constantly undergone rapid mutations for better adaptation in the host system. These newer mutations have given rise to several lineages/ variants of the virus that have resulted in high transmission and virulence rates compared to the previously circulating variants. Owing to this, the overall caseload and related mortality have tremendously increased globally to &gt; 233 million infections and &gt; 4.7 million deaths as of Sept. 28th, 2021. SARS-CoV-2, Spike (S) protein binds to host cells by recognizing human angiotensin-converting enzyme 2 (hACE2) receptor. The viral S protein contains S1 and S2 domains that constitute the binding and fusion machinery, respectively. Structural analysis of viral S protein reveals that the virus undergoes conformational flexibility and dynamicity to interact with the hACE2 receptor. The SARS-CoV-2 variants and mutations might be associated with affecting the conformational plasticity of S protein, potentially linked to its altered affinity, infectivity, and immunogenicity. This review focuses on the current circulating variants of SARS-CoV-2 and the structure-function analysis of key S protein mutations linked with increased affinity, higher infectivity, enhanced transmission rates, and immune escape against this infection.</AbstractText><CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Deepali</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biophysics, All India Institute of Medical Sciences, New Delhi,, Delhi, 110029, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, All India Institute of Medical Sciences, New Delhi,, Delhi, 110029, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biophysics, All India Institute of Medical Sciences, New Delhi,, Delhi, 110029, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Mukesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biophysics, All India Institute of Medical Sciences, New Delhi,, Delhi, 110029, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ethayathulla</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Biophysics, All India Institute of Medical Sciences, New Delhi,, Delhi, 110029, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Punit</ForeName><Initials>P</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7358-3716</Identifier><AffiliationInfo><Affiliation>Department of Biophysics, All India Institute of Medical Sciences, New Delhi,, Delhi, 110029, India. punitkaur@aiims.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IWYS04</GrantID><Agency>Indian Council of Medical Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cell Mol Life Sci</MedlineTA><NlmUniqueID>9705402</NlmUniqueID><ISSNLinking>1420-682X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lineages</Keyword><Keyword MajorTopicYN="N">S protein</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Structure-functional analysis</Keyword><Keyword MajorTopicYN="N">Variant of concern (VOC)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>17</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34731254</ArticleId><ArticleId IdType="doi">10.1007/s00018-021-04008-0</ArticleId><ArticleId IdType="pii">10.1007/s00018-021-04008-0</ArticleId></ArticleIdList><ReferenceList><Title>References:</Title><Reference><Citation>Zheng J (2020) SARS-coV-2: An emerging coronavirus that causes a global threat. Int J Biol Sci 16:1678–1685. https://doi.org/10.7150/ijbs.45053</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.45053</ArticleId><ArticleId IdType="pubmed">32226285</ArticleId><ArticleId IdType="pmcid">7098030</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91:157–160. https://doi.org/10.23750/abm.v91i1.9397</Citation></Reference><Reference><Citation>COVID Live Update: 233,158,434 Cases and 4,771,151 Deaths from the Coronavirus - Worldometer. https://www.worldometers.info/coronavirus/ . Accessed 28 Sep 2021.</Citation></Reference><Reference><Citation>Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ . Accessed 27 Sept 2021.</Citation></Reference><Reference><Citation>Lo Presti A, Rezza G, Stefanelli P (2020) Selective pressure on SARS-CoV-2 protein coding genes and glycosylation site prediction. Heliyon 6:e05001. https://doi.org/10.1016/j.heliyon.2020.e05001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e05001</ArticleId><ArticleId IdType="pubmed">32984566</ArticleId><ArticleId IdType="pmcid">7505600</ArticleId></ArticleIdList></Reference><Reference><Citation>GISAID - Initiative. https://www.gisaid.org/ . Accessed 27 Sept 2021</Citation></Reference><Reference><Citation>Salvatori G, Luberto L, Maffei M et al (2020) SARS-CoV-2 spike protein: An optimal immunological target for vaccines. J Transl Med 18:222. https://doi.org/10.1186/s12967-020-02392-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02392-y</ArticleId><ArticleId IdType="pubmed">32493510</ArticleId><ArticleId IdType="pmcid">7268185</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, Zhou L, Ma Z et al (2021) Promising Immunotherapies against COVID-19. Adv Ther. https://doi.org/10.1002/adtp.202100044</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.202100044</ArticleId><ArticleId IdType="pubmed">34816373</ArticleId><ArticleId IdType="pmcid">8189944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai C, Zhong Q, Gao GF (2021) Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci. https://doi.org/10.1007/S11427-021-1964-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11427-021-1964-4</ArticleId><ArticleId IdType="pubmed">34735681</ArticleId><ArticleId IdType="pmcid">8362648</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, Patel KJ, Ranjan K (2021) COVID-19: unmasking emerging SARS-CoV-2 variants vaccines and therapeutic strategies. Biomolecules 11:993. https://doi.org/10.3390/biom11070993</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11070993</ArticleId><ArticleId IdType="pubmed">34356617</ArticleId><ArticleId IdType="pmcid">8301790</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastogi M, Pandey N, Shukla A, Singh SK (2020) SARS coronavirus 2: from genome to infectome. Respir Res 21:318. https://doi.org/10.1186/s12931-020-01581-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01581-z</ArticleId><ArticleId IdType="pubmed">33261606</ArticleId><ArticleId IdType="pmcid">7706175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P, Pandey R, Sharma P, et al (2020) Integrated genomic view of SARS-CoV-2 in India. Wellcome open research. 5:184. https://doi.org/10.12688/wellcomeopenres.16119.1</Citation></Reference><Reference><Citation>Yadav R, Chaudhary JK, Jain N et al (2021) Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 10:821. https://doi.org/10.3390/cells10040821</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040821</ArticleId><ArticleId IdType="pubmed">33917481</ArticleId><ArticleId IdType="pmcid">8067447</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F (2016) Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 3:237–261. https://doi.org/10.1146/annurev-virology-110615-042301</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-110615-042301</ArticleId><ArticleId IdType="pubmed">27578435</ArticleId><ArticleId IdType="pmcid">5457962</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemm T, Ebert G, Calleja DJ, et al (2020) Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J. 39(18): e106275. https://doi.org/10.15252/embj.2020106275</Citation></Reference><Reference><Citation>Jauregui AR, Savalia D, Lowry VK et al (2013) Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling. PLoS ONE 8:e62416. https://doi.org/10.1371/journal.pone.0062416</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062416</ArticleId><ArticleId IdType="pubmed">23658627</ArticleId><ArticleId IdType="pmcid">3639174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson BS, Kolte V, Khan A, Sharma G (2020) Dynamic tracking of variant frequencies depicts the evolution of mutation sites amongst SARS-CoV-2 genomes from India. J Med Virol 93:2534–2537. https://doi.org/10.1002/jmv.26756</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26756</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyton RJ, Altmann DM (2021) Risk of SARS-CoV-2 reinfection after natural infection. Lancet 397:1161–1163. https://doi.org/10.1016/S0140-6736(21)00662-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00662-0</ArticleId><ArticleId IdType="pubmed">33743219</ArticleId><ArticleId IdType="pmcid">7969128</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Gao GF (2021) Viral targets for vaccines against COVID-19. Nat Rev Immunol 21:73–82. https://doi.org/10.1038/s41577-020-00480-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00480-0</ArticleId><ArticleId IdType="pubmed">33340022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi MK, Singh P, Sharma S et al (2020) Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor. J Biomol Struct Dyn 39:1–14. https://doi.org/10.1080/07391102.2020.1790425</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1790425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G, Zhu C, Zhu Y, Sun F (2020) Minireview of progress in the structural study of SARS-CoV-2 proteins. Curr Res Microb Sci 1:53–61. https://doi.org/10.1016/j.crmicr.2020.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmicr.2020.06.003</ArticleId><ArticleId IdType="pubmed">33236001</ArticleId><ArticleId IdType="pmcid">7323663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi MK, Nath A, Singh TP et al (2021) Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery. Mol Divers 25:1439–1460. https://doi.org/10.1007/s11030-021-10256-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11030-021-10256-w</ArticleId><ArticleId IdType="pubmed">34159484</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha UK (2021) SARS-CoV-2 vaccines and their challenges against the variants. J Adv Intern Med 10:1–3. https://doi.org/10.3126/jaim.v10i1.37080</Citation><ArticleIdList><ArticleId IdType="doi">10.3126/jaim.v10i1.37080</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Lou Z, Liu Y et al (2004) Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 279:49414–49419. https://doi.org/10.1074/jbc.M408782200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M408782200</ArticleId><ArticleId IdType="pubmed">15345712</ArticleId></ArticleIdList></Reference><Reference><Citation>Belouzard S, Millet JK, Licitra BN, Whittaker GR (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4:1011–1033. https://doi.org/10.3390/v4061011</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v4061011</ArticleId><ArticleId IdType="pubmed">22816037</ArticleId><ArticleId IdType="pmcid">3397359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId><ArticleId IdType="pmcid">7102627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail AM, Elfiky AA (2020) SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic. Signal Transduct Target Ther 5:252. https://doi.org/10.1038/s41392-020-00365-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00365-7</ArticleId><ArticleId IdType="pubmed">33127886</ArticleId><ArticleId IdType="pmcid">7596835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Zhang J, Xiao T et al (2020) Distinct conformational states of SARS-CoV-2 spike protein. Science 369:1586–1592. https://doi.org/10.1126/science.abd4251</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4251</ArticleId><ArticleId IdType="pubmed">32694201</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W (2020) Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific J Allergy Immunol. 38:10–18. https://doi.org/10.12932/AP-200220-0773</Citation></Reference><Reference><Citation>Perlot T, Penninger JM (2013) ACE2 - From the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect 15:866–873. https://doi.org/10.1016/j.micinf.2013.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2013.08.003</ArticleId><ArticleId IdType="pubmed">23962453</ArticleId><ArticleId IdType="pmcid">7110844</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia P, Cavallini C, Spanevello A, Angeli F (2020) The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 76:14–20. https://doi.org/10.1016/j.ejim.2020.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.04.037</ArticleId><ArticleId IdType="pubmed">32336612</ArticleId><ArticleId IdType="pmcid">7167588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, Ge J, Yu J et al (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581:215–220. https://doi.org/10.1038/s41586-020-2180-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Ye G, Shi K et al (2020) Structural basis of receptor recognition by SARS-CoV-2. Nature 581:221–224. https://doi.org/10.1038/s41586-020-2179-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId><ArticleId IdType="pmcid">7328981</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B et al (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409–424. https://doi.org/10.1038/s41579-021-00573-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Janik E, Niemcewicz M, Podogrocki M et al (2021) The emerging concern and interest sars-cov-2 variants. Pathogens 10:633. https://doi.org/10.3390/pathogens10060633</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060633</ArticleId><ArticleId IdType="pubmed">34064143</ArticleId><ArticleId IdType="pmcid">8224338</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikhra V (2021) Evolving Patterns in COVID-19: The Virus, its Variants and Infectivity-cum-Virulence. Biomed J Sci Tech Res 33:25712–25722: https://doi.org/10.26717/bjstr.2021.33.005382</Citation></Reference><Reference><Citation>Hadfield J, Megill C, Bell SM et al (2018) NextStrain: Real-time tracking of pathogen evolution. Bioinformatics 34:4121–4123. https://doi.org/10.1093/bioinformatics/bty407</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty407</ArticleId><ArticleId IdType="pubmed">29790939</ArticleId><ArticleId IdType="pmcid">6247931</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Holmes EC, O’Toole Á et al (2020) A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 5:1403–1407. https://doi.org/10.1038/s41564-020-0770-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId><ArticleId IdType="pmcid">7610519</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Y, McCauley J (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. Eurosurveillance 22:30494. 10. 2807/1560–7917.ES.2017.22.13.30494</Citation></Reference><Reference><Citation>Koyama T, Platt D, Parida L (2020) Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ 98:495–504. https://doi.org/10.2471/BLT.20.253591</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.20.253591</ArticleId><ArticleId IdType="pubmed">32742035</ArticleId><ArticleId IdType="pmcid">7375210</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamed SM, Elkhatib WF, Khairalla AS, Noreddin AM (2021) Global dynamics of SARS-CoV-2 clades and their relation to COVID-19 epidemiology. Sci Rep 11:8435. https://doi.org/10.1038/s41598-021-87713-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-87713-x</ArticleId><ArticleId IdType="pubmed">33875719</ArticleId><ArticleId IdType="pmcid">8055906</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft, E. CoVariants (2021): SARS-CoV-2 mutations and variants of interest (NextStrain). CoVariants  https://covariants.org/2021 .</Citation></Reference><Reference><Citation>Public Health England (2020), Investigation of novel SARS-COV-2 variant: Variant of Concern 2020/12/01. https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201 .</Citation></Reference><Reference><Citation>Embrace the WHO’s new naming system for coronavirus variants (2021). Nature 594:149. https://doi.org/10.1038/d41586-021-01508-8</Citation></Reference><Reference><Citation>Konings F, Perkins MD, Kuhn JH et al (2021) SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nat Microbiol 6:821–823. https://doi.org/10.1038/s41564-021-00932-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00932-w</ArticleId><ArticleId IdType="pubmed">34108654</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Candelas F, Shaw MA, Phan T et al (2021) One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. J Infect Genet Evol 92:104869. https://doi.org/10.1016/j.meegid.2021.104869</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2021.104869</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England (2020) Investigation of novel SARS-COV-2 variant: Variant of Concern 2020/12/01 Technical Briefing 3. GovUk 1–11; https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950823/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3_-_England.pdf .</Citation></Reference><Reference><Citation>B.1.1.207 Overview, Nomenclature, Criteria for notability, Notable variants, The Free Encyclopedia (2021). https://www.mobilewiki.org/en/B.1.1.207-6666680484 . Accessed 11 May 2021.</Citation></Reference><Reference><Citation>Galloway SE, Paul P, MacCannell DR, et al (2021) Emergence of SARS-CoV-2 B.1.1.7 Lineage. Mmwr 70:95–99. https://doi.org/10.15585/mmwr.mm7003e2</Citation></Reference><Reference><Citation>Frampton D, Rampling T, Cross A et al (2021) Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis 21:1246–1256. https://doi.org/10.1016/S1473-3099(21)00170-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00170-5</ArticleId><ArticleId IdType="pubmed">33857406</ArticleId><ArticleId IdType="pmcid">8041359</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Toole Á, Kraemer MUG, Hill V, et al (2021) Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2. Wellcome Open Res 6:121. https://doi.org/10.12688/wellcomeopenres.16661.1</Citation></Reference><Reference><Citation>Feder KA, Pearlowitz M, Goode A, et al (2021) Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January–February 2021. MMWR Morb Mortal Wkly Rep 70:627–631. https://doi.org/10.15585/mmwr.mm7017a5</Citation></Reference><Reference><Citation>Kim YJ, Jang US, Soh SM, et al (2021) The impact on infectivity and neutralization efficiency of sars-cov-2 lineage b.1.351 pseudovirus. Viruses 13:633. https://doi.org/10.3390/v13040633</Citation></Reference><Reference><Citation>Oliveira MDL, Oliveira KMT, Silva JN, et al (2021) Theoretical causes of the Brazilian P.1 and P.2 lineages of the SARS-CoV-2 virus through molecular dynamics. bioRxiv 2021.04.09.439181. doi:  https://doi.org/10.1101/2021.04.09.439181</Citation></Reference><Reference><Citation>Hirotsu Y, Omata M (2021) Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu. Japan J Infect 82:276–316. https://doi.org/10.1016/j.jinf.2021.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.03.013</ArticleId><ArticleId IdType="pubmed">33766552</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava S, Banu S, Singh P et al (2021) SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants. J Biosci 46:22. https://doi.org/10.1007/s12038-021-00145-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12038-021-00145-7</ArticleId><ArticleId IdType="pubmed">33737495</ArticleId><ArticleId IdType="pmcid">7895735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V, Singh J, Hasnain SE, Sundar D (2021) Possible link between higher transmissibility of B.1.617 and B.1.1.7 variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity. Int J Mol Sc 22:9131. https://doi.org/10.3390/ijms22179131</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179131</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian S, Potdar V, Jadhav S, et al (2021) Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv 2021.04.22.440932. https://doi.org/10.1101/2021.04.22.440932</Citation></Reference><Reference><Citation>Singh J, Rahman SA, Ehtesham NZ et al (2021) SARS-CoV-2 variants of concern are emerging in India. Nat Med 27:1131–1133. https://doi.org/10.1038/s41591-021-01397-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01397-4</ArticleId><ArticleId IdType="pubmed">34045737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav PD, Sapkal GN, Abraham P, et al (2021) Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1. Clin Infect Di, ciab483. https://doi.org/10.1093/cid/ciab483</Citation></Reference><Reference><Citation>McCallum M, Bassi J, Marco A De, et al (2021) SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv 2021.03.31.437925. https://doi.org/10.1101/2021.03.31.437925</Citation></Reference><Reference><Citation>Deng X, Garcia-Knight MA, Khalid MM et al (2021) Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184:3426-3437.e8. https://doi.org/10.1016/j.cell.2021.04.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.025</ArticleId><ArticleId IdType="pubmed">33991487</ArticleId><ArticleId IdType="pmcid">8057738</ArticleId></ArticleIdList></Reference><Reference><Citation>Voloch CM, da Silva FR, de Almeida LGP et al (2020) Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J Virol 95:e00119-e121. https://doi.org/10.1101/2020.12.23.20248598</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.23.20248598</ArticleId></ArticleIdList></Reference><Reference><Citation>Goes LR, Siqueira JD, Garrido MM et al (2021) New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro. Brazil Infect Genet Evol 94:104998. https://doi.org/10.1016/j.meegid.2021.104998</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2021.104998</ArticleId><ArticleId IdType="pubmed">34252616</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick KD, Jacobs JL, Mellors JW (2021) The emerging plasticity of SARS-CoV-2. Science 371:1306–1308. https://doi.org/10.1126/science.abg4493</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg4493</ArticleId><ArticleId IdType="pubmed">33766871</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew N, Bascos D, Mirano-Bascos D, Saloma CP (2021) Structural Analysis of Spike Protein Mutations in the SARS-CoV-2 P.3 Variant. bioRxiv 2021.03.06.434059. https://doi.org/10.1101/2021.03.06.434059</Citation></Reference><Reference><Citation>Annavajhala MK, Mohri H, Zucker JE, et al (2021) A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv 2021.02.23.21252259v4. https://doi.org/10.1101/2021.02.23.21252259</Citation></Reference><Reference><Citation>Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ . Accessed 2 Jun 2021</Citation></Reference><Reference><Citation>Isabel S, Graña-Miraglia L, Gutierrez JM et al (2020) Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci Rep 10:14031. https://doi.org/10.1038/s41598-020-70827-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70827-z</ArticleId><ArticleId IdType="pubmed">32820179</ArticleId><ArticleId IdType="pmcid">7441380</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Jackson CB, Mou H, et al (2020) The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv 2020.06.12.148726. https://doi.org/10.1101/2020.06.12.148726</Citation></Reference><Reference><Citation>Raghav S, Ghosh A, Turuk J et al (2020) Analysis of Indian SARS-CoV-2 Genomes Reveals Prevalence of D614G Mutation in Spike Protein Predicting an Increase in Interaction With TMPRSS2 and Virus Infectivity. Front Microbiol 11:594928. https://doi.org/10.3389/fmicb.2020.594928</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.594928</ArticleId><ArticleId IdType="pubmed">33329480</ArticleId><ArticleId IdType="pmcid">7732478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, He CL, Gao QZ, et al (2020) D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity. bioRxiv 2020.06.20.161323. https://doi.org/10.1101/2020.06.20.161323</Citation></Reference><Reference><Citation>Yurkovetskiy L, Wang X, Pascal KE et al (2020) Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183:739-751.e8. https://doi.org/10.1016/j.cell.2020.09.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.032</ArticleId><ArticleId IdType="pubmed">32991842</ArticleId><ArticleId IdType="pmcid">7492024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Mannar D, Srivastava SS et al (2021) Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol 19:e3001237. https://doi.org/10.1371/journal.pbio.3001237</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001237</ArticleId><ArticleId IdType="pubmed">33914735</ArticleId><ArticleId IdType="pmcid">8112707</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeramachaneni GK, Thunuguntla VBSC, Bobbillapati J, Bondili JS (2020) Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor. J Biomol Struct Dyn 39:4015–4025. https://doi.org/10.1080/07391102.2020.1773318</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1773318</ArticleId><ArticleId IdType="pubmed">32448098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali F, Kasry A, Amin M (2021) The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant. Med Drug Discov 10:100086. https://doi.org/10.1016/j.medidd.2021.100086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2021.100086</ArticleId><ArticleId IdType="pubmed">33681755</ArticleId><ArticleId IdType="pmcid">7923861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L, Song S, Zhou B et al (2021) Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. Virol J 18:87. https://doi.org/10.1186/s12985-021-01554-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01554-8</ArticleId><ArticleId IdType="pubmed">33910569</ArticleId><ArticleId IdType="pmcid">8081001</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan B, Wang H, Huynh T (2021) Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations. FEBS Lett 595:1454–1461. https://doi.org/10.1002/1873-3468.14076</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.14076</ArticleId><ArticleId IdType="pubmed">33728680</ArticleId><ArticleId IdType="pmcid">8250610</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JC, Passos GA (2021) The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation. bioRxiv 2020.12.29.424708. https://doi.org/10.1101/2020.12.29.424708</Citation></Reference><Reference><Citation>Koirala RP, Thapa B, Khanal SP et al (2021) Binding of sars-cov-2/sars-cov spike protein with human ace2 receptor. J Phys Commun 5:035010. https://doi.org/10.1088/2399-6528/abea27</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/2399-6528/abea27</ArticleId></ArticleIdList></Reference><Reference><Citation>Villoutreix BO, Calvez V, Marcelin AG, Khatib AM (2021) In silico investigation of the new UK (B.1.1.7) and South African (501y.v2) SARS-CoV-2 variants with a focus at the ace2-spike rbd interface. Int J Mol Sci 22:1–13. https://doi.org/10.3390/ijms22041695</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041695</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Maggi F (2021) Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. https://doi.org/10.1002/rmv.2231.10.1002/rmv.2231</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2231.10.1002/rmv.2231</ArticleId><ArticleId IdType="pubmed">33724631</ArticleId><ArticleId IdType="pmcid">8250244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H, Wilkinson E, Giovanetti M et al (2021) Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592:438–443. https://doi.org/10.1038/s41586-021-03402-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03402-9</ArticleId><ArticleId IdType="pubmed">33690265</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A, Zia T, Suleman M et al (2021) Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data. J Cell Physiol 236:7045–7057. https://doi.org/10.1002/jcp.30367</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30367</ArticleId><ArticleId IdType="pubmed">33755190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson EC, Rosen LE, Shepherd JG et al (2021) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184:1171-1187.e20. https://doi.org/10.1016/j.cell.2021.01.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.037</ArticleId><ArticleId IdType="pubmed">33621484</ArticleId><ArticleId IdType="pmcid">7843029</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Kemp SA, Papa G et al (2021) Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep 35:109292. https://doi.org/10.1016/j.celrep.2021.109292</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109292</ArticleId><ArticleId IdType="pubmed">34166617</ArticleId><ArticleId IdType="pmcid">8185188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Zhang L, Zhang Y et al (2021) The antigenicity of epidemic SARS-CoV-2 variants in the United Kingdom. Front Immunol 12:687869. https://doi.org/10.3389/fimmu.2021.687869</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.687869</ArticleId><ArticleId IdType="pubmed">34220844</ArticleId><ArticleId IdType="pmcid">8247764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Xu C, Wang P et al (2020) N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation. Front cell dev bio 9:697035. https://doi.org/10.3389/fcell.2021.697035</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.697035</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, Steinkellner G, Köchl K et al (2021) Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2. Sci Rep 11:4320. https://doi.org/10.1038/s41598-021-83761-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83761-5</ArticleId><ArticleId IdType="pubmed">33619331</ArticleId><ArticleId IdType="pmcid">7900180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Chen J, Gao K, Wei GW (2021) Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. Genomics 113:2158–2170. https://doi.org/10.1016/j.ygeno.2021.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2021.05.006</ArticleId><ArticleId IdType="pubmed">34004284</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo SA, Bukhari IA, Akram J, et al (2021) COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci 25:1663–1679. https://doi.org/10.26355/eurrev_202102_24877</Citation></Reference><Reference><Citation>Mejdani M, Haddadi K, Pham C, Mahadevan R (2021) SARS-CoV-2 receptor binding mutations and antibody contact sites. Antib Ther 4:149–158. https://doi.org/10.1093/abt/tbab015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abt/tbab015</ArticleId><ArticleId IdType="pubmed">34386694</ArticleId><ArticleId IdType="pmcid">8353666</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha UK (2021) B.1.617.2 variant and increasing surge of COVID-19 in Nepal. Nepal Mediciti Med J 2:1–4. https://doi.org/10.3126/nmmj.v2i1.37212</Citation><ArticleIdList><ArticleId IdType="doi">10.3126/nmmj.v2i1.37212</ArticleId></ArticleIdList></Reference><Reference><Citation>Barona-Gomez F, Delaye L, Diaz-Valenzuela E, et al (2021) Phylogenomics and population genomics of SARS-CoV-2 in Mexico reveals variants of interest (VOI) and a mutation in the Nucleocapsid protein associated with symptomatic versus asymptomatic carriers. medRxiv 2021.05.18.21256128v2. https://doi.org/10.1101/2021.05.18.21256128</Citation></Reference><Reference><Citation>Di Giacomo S, Mercatelli D, Rakhimov A, Giorgi FM (2021) Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J Med Virol 93:5638–5643. https://doi.org/10.1002/jmv.27062</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27062</ArticleId><ArticleId IdType="pubmed">33951211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty S (2021) Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. Biochem Biophys Res Commun 534:374–380. https://doi.org/10.1016/j.bbrc.2020.11.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.11.075</ArticleId><ArticleId IdType="pubmed">33272568</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Gao K, Wang R, Wei G-W (2021) Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. bioRxiv 2021.04.12.439473. https://doi.org/10.1101/2021.04.12.439473</Citation></Reference><Reference><Citation>Grabowski F, Preibisch G, Giziński S et al (2021) Sars-cov-2 variant of concern 202012/01 has about twofold replicative advantage and acquires concerning mutations. Viruses 13:392. https://doi.org/10.3390/v13030392</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030392</ArticleId><ArticleId IdType="pubmed">33804556</ArticleId><ArticleId IdType="pmcid">8000749</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney AJ, Loes AN, Crawford KHD et al (2021) Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29:463-476.e6. https://doi.org/10.1016/j.chom.2021.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId><ArticleId IdType="pmcid">7869748</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffeber C, de Koning K, Kanaar R, Lebbink JHG (2021) Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants. J Mol Biol 433:167058. https://doi.org/10.1016/j.jmb.2021.167058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167058</ArticleId><ArticleId IdType="pubmed">34023401</ArticleId><ArticleId IdType="pmcid">8139174</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, VanBlargan LA, Bloyet LM et al (2021) Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29:477-488.e4. https://doi.org/10.1016/j.chom.2021.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.01.014</ArticleId><ArticleId IdType="pubmed">33535027</ArticleId><ArticleId IdType="pmcid">7839837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Dcosta BM, Samanovic MI, et al (2021) The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India 1 Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal 2 Antibodies. bioRxiv 2021.05.14.444076. https://doi.org/10.1101/2021.05.14.444076</Citation></Reference><Reference><Citation>Cherian S, Potdar V, et al (2021) Convergent evolution of SARS-CoV2 spike mutations, L452R, E484Q and P681R, in the second wave of Covid-19 in Maharashtra, India. bioRxiv 2021.04.22.440932. https://doi.org/10.1101/2021.04.22.440932</Citation></Reference><Reference><Citation>Devendran R, Kumar M, Chakraborty S (2020) Genome analysis of SARS-CoV-2 isolates occurring in India: Present scenario. Indian J public health 64:S147–S155. https://doi.org/10.4103/ijph.IJPH_506_20</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijph.IJPH_506_20</ArticleId><ArticleId IdType="pubmed">32496247</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattabiraman C, Prasad P, George AK, et al (2021) Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. Wellcome Open Res 6:110. https://doi.org/10.12688/wellcomeopenres.16768.1</Citation></Reference><Reference><Citation>Yadav PD, Nyayanit DA, Majumdar T et al (2021) An epidemiological analysis of sars-cov-2 genomic sequences from different regions of India. Viruses 13:925. https://doi.org/10.3390/v13050925</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050925</ArticleId><ArticleId IdType="pubmed">34067745</ArticleId><ArticleId IdType="pmcid">8156686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rani PR, Imran M, Lakshmi JV et al (2021) Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape. J Med Virol 93:4163–4165. https://doi.org/10.1002/jmv.26997</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26997</ArticleId><ArticleId IdType="pubmed">33818797</ArticleId><ArticleId IdType="pmcid">8250729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandel D, Gupta D, Sah V, Harinivas Harshan K (2021) N440K variant of SARS-CoV-2 has Higher Infectious Fitness. bioRxiv. 2021.04.30.441434. https://doi.org/10.1101/2021.04.30.441434</Citation></Reference><Reference><Citation>Singh J, Samal J, Kumar V, et al (2021) Structure-function analyses of new sars-cov-2 variants b.1.1.7, b.1.351 and b.1.1.28.1: Clinical, diagnostic, therapeutic and public health implications. Viruses 13:439. https://doi.org/10.3390/v13030439</Citation></Reference><Reference><Citation>Tada T, Dcosta BM, Zhou H, et al (2021) Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. bioRxiv 2021.02.18.431897. https://doi.org/10.1101/2021.02.18.431897</Citation></Reference><Reference><Citation>Hansen J, Baum A, Pascal KE et al (2020) Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369:1010–1014. https://doi.org/10.1126/science.abd0827</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0827</ArticleId><ArticleId IdType="pubmed">32540901</ArticleId><ArticleId IdType="pmcid">7299284</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese M, Jiang B, Iwai N et al (2021) A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations. J Clin Microbiol 59:e0074121. https://doi.org/10.1128/jcm.00741-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00741-21</ArticleId><ArticleId IdType="pubmed">33952596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortuso F, Mercatelli D, Guzzi PH, Giorgi FM (2021) Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2021.1886175</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1886175</ArticleId><ArticleId IdType="pubmed">33583326</ArticleId><ArticleId IdType="pmcid">7885719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayarri-Olmos R, Rosbjerg A, Johnsen LB et al (2021) The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. J Biol Chem 296:100536. https://doi.org/10.1016/j.jbc.2021.100536</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100536</ArticleId><ArticleId IdType="pubmed">33716040</ArticleId><ArticleId IdType="pmcid">7948531</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M, Liu H, Wu NC et al (2020) Structural basis of a shared antibody response to SARS-CoV-2. Science 369:1119–1123. https://doi.org/10.1126/science.abd2321</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2321</ArticleId><ArticleId IdType="pubmed">32661058</ArticleId><ArticleId IdType="pmcid">7402627</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay V, Lucas A, Panja S, Mallela K (2021) Interplay between protein stability, binding to ACE2 and escape from neutralizing antibodies determines the natural selection of SARS-CoV-2 receptor binding domain variants. bioRxiv 2021.05.23.445348. https://doi.org/10.1101/2021.05.23.445348</Citation></Reference><Reference><Citation>Takuma H, Yaegashi. N, Ikuo K (2021) Effect of RBD (Y453F) mutation in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity. medRxiv 2021.01.28.21250577v2. https://doi.org/10.1101/2021.01.28.21250577</Citation></Reference><Reference><Citation>Colson P, Levasseur A, Delerce J et al (2021) Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage. Clin Microbiol Infect 27:1352.e1-1352.e5. https://doi.org/10.1016/j.cmi.2021.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallm J-P, Bundschuh C, Kim H, et al (2021) Local emergence and decline of a SARS-CoV-2 variant with mutations L452R and N501Y in the spike protein. medRxiv 2021.04.27.21254849v1. https://doi.org/10.1101/2021.04.27.21254849</Citation></Reference><Reference><Citation>Manickavasagam P (2020) Spike protein of SARS-CoV-2: Impact of single amino acid mutation and effect of drug binding to the variant-in silico analysis. Preprints. https://doi.org/10.20944/preprints202008.0447.v1</Citation></Reference><Reference><Citation>Zuckerman NS, Fleishon S, Bucris E, et al (2021) A unique SARS-CoV-2 spike protein P681H strain detected in Israel Israel National Consortium for SARS-CoV-2 sequencing. medRxiv 2021.03.25.21253908v1. https://doi.org/10.1101/2021.03.25.21253908</Citation></Reference><Reference><Citation>Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, et al (2021) Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol 95:105038. https://doi.org/10.1016/j.meegid.2021.10503</Citation></Reference><Reference><Citation>Meng B, Kemp SA, Papa G, et al. (2021) Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep 35:109292. https://doi.org/10.1016/j.celrep.2021.109292</Citation></Reference><Reference><Citation>Peacock TP, Sheppard CM, Brown JC, et al (2021) The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin. bioRxiv 2021.05.28.446163. https://doi.org/10.1101/2021.05.28.446163</Citation></Reference><Reference><Citation>Yadav PD, Mohandas S, Shete AM, et al (2021) SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. bioRxiv 2021.05.05.442760. https://doi.org/10.1101/2021.05.05.442760</Citation></Reference><Reference><Citation>Shirakawa K, Sadamasu K, Kimura I, et al (2021) SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion. bioRxiv 2021.06.17.448820.  https://doi.org/10.1101/2021.06.17.448820</Citation></Reference><Reference><Citation>Ferreira I, Datir R, Papa G, et al (2021) SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. bioRxiv 2021.05.08.443253. https://doi.org/10.1101/2021.05.08.443253 .</Citation></Reference><Reference><Citation>McCallum M, De Marco A, Lempp FA et al (2021) N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184:2332-2347.e16. https://doi.org/10.1016/j.cell.2021.03.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.028</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId><ArticleId IdType="pmcid">7962585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok SM (2021) An NTD supersite of attack. Cell Host Microbe 29:744–746. https://doi.org/10.1016/j.chom.2021.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.04.010</ArticleId><ArticleId IdType="pubmed">33984277</ArticleId><ArticleId IdType="pmcid">8114578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G, Guo Y, Zhou T et al (2021) Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29:819-833.e7. https://doi.org/10.1016/j.chom.2021.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.005</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId><ArticleId IdType="pmcid">7953435</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega-Magaña N, Sánchez-Sánchez R, Hernández-Bello J et al (2021) RT-qPCR Assays for Rapid Detection of the N501Y, 69–70del, K417N, and E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants With Clinical Impact. Front Cell Infect Microbiol 11:672562. https://doi.org/10.3389/fcimb.2021.672562</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.672562</ArticleId><ArticleId IdType="pubmed">34123874</ArticleId><ArticleId IdType="pmcid">8195289</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacisuleyman E, Hale C, Saito Y et al (2021) Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med 384:2212–2218. https://doi.org/10.1056/nejmoa2105000</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2105000</ArticleId><ArticleId IdType="pubmed">33882219</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar MS, Marwal R, Ponnusamy K, et al (2021) Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. medRxiv 2021.06.02.21258076. https://doi.org/10.1101/2021.06.02.21258076</Citation></Reference><Reference><Citation>Laha S, Chakraborty J, Das S et al (2020) Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol 85:104445. https://doi.org/10.1016/j.meegid.2020.104445</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104445</ArticleId><ArticleId IdType="pubmed">32615316</ArticleId><ArticleId IdType="pmcid">7324922</ArticleId></ArticleIdList></Reference><Reference><Citation>Osina NA, Krasnov YM, Guseva NP, et al (2021) Molecular-genetic monitoring of sARs-CoV-2 genovariants in the territory of the volga federal district of the Russian Federation. Communication. Probl Osobo Opasnykh Infektsii 122–127. https://doi.org/10.21055/0370-1069-2021-1-122-127</Citation></Reference><Reference><Citation>Toovey OTR, Harvey KN, Bird PW, Tang JWTWT (2021) Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK. J Infect 82:e23–e24. https://doi.org/10.1016/j.jinf.2021.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.025</ArticleId><ArticleId IdType="pubmed">33548358</ArticleId><ArticleId IdType="pmcid">7857057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai HY, Cai A (2021) SARS-CoV2 spike protein gene variants with N501T and G142D mutation–dominated infections in mink in the United States. J Vet Diagnostic Investig 33(5):939–942. https://doi.org/10.1177/10406387211023481</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10406387211023481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolini B, Rueca M, Gruber CEM, et al (2020) The newly introduced SARS-CoV-2 variant A222V is rapidly spreading in Lazio region, Italy. medRxiv 2020.11.28.20237016v1. https://doi.org/10.1101/2020.11.28.20237016</Citation></Reference><Reference><Citation>Gunadi WH, Hakim MS et al (2021) Molecular epidemiology of SARS-CoV-2 isolated from COVID-19 family clusters. BMC Med Genomics 14:144. https://doi.org/10.1186/s12920-021-00990-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-021-00990-3</ArticleId><ArticleId IdType="pubmed">34074255</ArticleId><ArticleId IdType="pmcid">8169432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashwaq O, Manickavasagam P, Haque SM (2021) V483A: an emerging mutation hotspot of SARS-CoV-2. Future Virol 16:419–429. https://doi.org/10.2217/fvl-2020-0384</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2020-0384</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wu J, Nie J et al (2020) The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 82:1284-1294.e9. https://doi.org/10.1016/j.cell.2020.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamad S, Hema K, Gupta D (2021) Structural stability predictions and molecular dynamics simulations of RBD and HR1 mutations associated with SARS-CoV-2 spike glycoprotein. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2021.1889671</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1889671</ArticleId><ArticleId IdType="pubmed">34243689</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleem A, Akbar Samad AB, Slenker AK (2021) Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). Treasure Island (FL) StatPearls Publishing, In StatPearls</Citation></Reference><Reference><Citation>Cristina Resende P, Naveca FG, Lins RD, et al (2021) The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the Spike protein. Virus evolution 7:veab069. https://doi.org/10.1093/ve/veab069</Citation></Reference><Reference><Citation>Winger A, Caspari T (2021) The spike of concern-the novel variants of Sars-cov-2. Viruses 13:1002. https://doi.org/10.3390/v13061002</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061002</ArticleId><ArticleId IdType="pubmed">34071984</ArticleId><ArticleId IdType="pmcid">8229995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir R et al (2020) Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. Preprint medRxiv. https://doi.org/10.1101/2020.12.05.20241927</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.05.20241927</ArticleId><ArticleId IdType="pubmed">33398302</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi VB, Caldana GD, de Menezes MA et al (2021) Genomic epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul. Brazil BMC Genomics 22:371. https://doi.org/10.1186/s12864-021-07708-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-021-07708-w</ArticleId><ArticleId IdType="pubmed">34016042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramírez-Soto MC, Arroyo-Hernández H, Ortega-Cáceres G (2021) Sex differences in the incidence, mortality, and fatality of COVID-19 in Peru. PLoS ONE 16:e0253193. https://doi.org/10.1371/journal.pone</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone</ArticleId><ArticleId IdType="pubmed">34125851</ArticleId><ArticleId IdType="pmcid">8202928</ArticleId></ArticleIdList></Reference><Reference><Citation>Jungreis I, Sealfon R, Kellis M (2021) SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. Nat Commun 2:2642. https://doi.org/10.1038/s41467-021-22905-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22905-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y, Omata M (2021) Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. PLoS Pathog. 17:e1009619. https://doi.org/10.1371/journal.ppat.1009619</Citation></Reference><Reference><Citation>Chrysostomou AC, Vrancken B, Koumbaris G et al (2021) A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic. Viruses 13:1098. https://doi.org/10.3390/v13061098</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061098</ArticleId><ArticleId IdType="pubmed">34207490</ArticleId><ArticleId IdType="pmcid">8227210</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochman, Nash D et al. (2020). Ongoing Global and Regional Adaptive Evolution of SARS-CoV-2. bioRxiv 2020.10.12.336644. https://doi.org/10.1101/2020.10.12.336644</Citation></Reference><Reference><Citation>V’kovski P, Kratzel A, Steiner S, et al (2021) Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19:155–170. https://doi.org/10.1038/s41579-020-00468-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo S, Liu K, Zheng J (2021) The genetic variant of sars-cov-2: Would it matter for controlling the devastating pandemic? Int J Biol Sci 17:1476–1485. https://doi.org/10.7150/ijbs.59137</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.59137</ArticleId><ArticleId IdType="pubmed">33907511</ArticleId><ArticleId IdType="pmcid">8071763</ArticleId></ArticleIdList></Reference><Reference><Citation>Om BB, N W, DF N, et al (2021) The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nat Med 27:1518–1524. https://doi.org/10.1038/S41591-021-01472-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41591-021-01472-W</ArticleId></ArticleIdList></Reference><Reference><Citation>PyMOL | pymol.org. https://pymol.org/2/ .</Citation></Reference><Reference><Citation>Warwicker J (2021) A model for pH coupling of the SARS-CoV-2 spike protein open/closed equilibrium. Brief Bioinform 22:1499–1507. https://doi.org/10.1093/bib/bbab056</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab056</ArticleId><ArticleId IdType="pubmed">33634309</ArticleId><ArticleId IdType="pmcid">8108619</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN et al (2021) Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371:850–854. https://doi.org/10.1126/science.abf9302</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf9302</ArticleId><ArticleId IdType="pubmed">33495308</ArticleId><ArticleId IdType="pmcid">7963219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir RP et al (2021) SARS-CoV-2 evolution during treatment of chronic infection. Nature 592:277–282. https://doi.org/10.1038/s41586-021-03291-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId><ArticleId IdType="pmcid">7610568</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakhmola S, Indari O, Kashyap D et al (2021) Mutational analysis of structural proteins of SARS-CoV-2. Heliyon 7:e06572. https://doi.org/10.1016/j.heliyon.2021.e06572</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e06572</ArticleId><ArticleId IdType="pubmed">33778179</ArticleId><ArticleId IdType="pmcid">7980187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Casner RG, Nair MS et al (2021) Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe 29:747-751.e4. https://doi.org/10.1016/j.chom.2021.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.04.007</ArticleId><ArticleId IdType="pubmed">33887205</ArticleId><ArticleId IdType="pmcid">8053237</ArticleId></ArticleIdList></Reference><Reference><Citation>Laha S et al (2020) Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. J Infect Genet Evol 85:104445. https://doi.org/10.1016/j.meegid.2020.104445</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104445</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew, N., Bascos, D., Mirano-Bascos, D., &amp; Saloma, C. P. (2021) Structural Analysis of Spike Protein Mutations in an Emergent SARS-CoV-2 Variant from the Philippines. bioRxiv 2021.03.06.434059. https://doi.org/10.1101/2021.03.06.434059</Citation></Reference><Reference><Citation>Maitra A et al (2020) Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility. J Biosci 45:76. https://doi.org/10.1007/s12038-020-00046-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12038-020-00046-1</ArticleId><ArticleId IdType="pubmed">32515358</ArticleId><ArticleId IdType="pmcid">7269891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>